12:00 AM
Jan 05, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

HQK-1001: Phase I data

A double-blind, placebo-controlled, 14-day Phase I trial in 41 healthy volunteers showed that 3 dosages (5, 10 and 15 mg/kg/day) of HQK-1001 were well tolerated with no significant adverse events....

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >